Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Juno Pharmaceuticals Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (256)
Cancellation by sponsor (71)
Prescription medicine registration (25)
Section 14, TGO91 consent (6)
Australian Public Assessment Report (AusPAR) (1)
Prescription medicine decision summary (1)

Date

2024 (11)
2023 (18)
2022 (36)
2021 (70)
2020 (45)
2019 (51)
2018 (18)
2017 (14)
2016 (14)
2015 (14)
2014 (7)
2013 (8)
2012 (12)
2011 (3)
2010 (1)
2009 (2)
2007 (1)
2006 (4)
2003 (7)
2000 (1)
1999 (5)
1998 (1)
1996 (3)
1994 (3)
1991 (11)

Results for "[search-keyword]"

Search

Sponsor content

360 result(s) found, displaying 81 to 90

POMOLIDE pomalidomide 4 mg hard gelatin capsule blister pack (335274)

18 May 2021

ARTG

Australian Register of Therapeutic Goods (ARTG) information for POMOLIDE pomalidomide 4 mg hard gelatin capsule blister pack.
IMATINIB AMNEAL imatinib (as mesilate) 400 mg capsules blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
IMATINIB AMNEAL imatinib (as mesilate) 100 mg capsules blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
JUNOXICLAV 500/100 amoxicillin (as sodium) 500 mg and clavulanic acid (as potassium clavulanate) 100mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
JUNOXICLAV 1000/200 amoxicillin (as sodium) 1000 mg and clavulanic acid (as potassium clavulanate) 200mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
JUNOXICLAV 2000/200 amoxicillin (as sodium) 2000 mg and clavulanic acid (as potassium clavulanate) 200mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
Oxaliplatin APOTEX oxaliplatin 100mg/20mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
GenRx Oxaliplatin oxaliplatin 50mg/10mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
Oxaliplatin APOTEX oxaliplatin 50mg/10mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
GenRx Oxaliplatin oxaliplatin 100mg/20mL concentrated injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd

Pages

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.